Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Phase 1 Cancer Trials

Baltimore, Maryland

Phase 1 cancer trials in Baltimore, MD

50 Phase 1 cancer studies are recruiting participants at sites in Baltimore as of November 17, 2026, according to ClinicalTrials.gov. Phase 1 Cancer Trials can help you understand your options and connect with a study team.

Call (888) 927-9038
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Baltimore at a glance

  • 50 studies are recruiting at a site in Baltimore.
  • By phase: Early Phase 1 (3), Phase 1 (25), Phase 1/2 (22).
  • By sponsor: industry (35), university, hospital or other (13), government (2).
  • By research area: Lung Cancer (20), Lymphoma (10), Prostate Cancer (9), Breast Cancer (7), Pancreatic Cancer (3), Melanoma (1).
  • Most recent update to one of these records: November 17, 2026.

Breast cancer studies recruiting in Baltimore

Basic details from each study's public record (the 30 most recently updated of 50). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Stemline Therapeutics, Inc.
    Study site
    Sidney Kimmel Comprehensive Cancer Center
    Registry record
    NCT06638307 · updated
  2. A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    AstraZeneca
    Registry record
    NCT05123482 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Baltimore, MD on ClinicalTrials.gov.

Lung cancer studies recruiting in Baltimore

  1. Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Johns Hopkins University/Sidney Kimmel Cancer Center · University of Maryland/Greenebaum Cancer Center
    Registry record
    NCT06287775 · updated
  2. A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Verastem, Inc.
    Study site
    Johns Hopkins University
    Registry record
    NCT07020221 · updated
  3. Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Synthekine
    Study site
    University of Maryland
    Registry record
    NCT05098132 · updated
  4. A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    AstraZeneca
    Registry record
    NCT06996782 · updated
  5. Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Exelixis
    Study site
    Exelixis Clinical Site #14
    Registry record
    NCT05176483 · updated
  6. DK222 Study at Hopkins

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Study site
    Johns Hopkins Hospital
    Registry record
    NCT07140315 · updated
  7. Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Revolution Medicines, Inc.
    Study site
    Johns Hopkins
    Registry record
    NCT07349537 · updated
  8. Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
    Study site
    University of Maryland Marlene & Stewart Greenebaum Comprehensive Cancer Center
    Registry record
    NCT06343402 · updated
  9. Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Study site
    Johns Hopkins University
    Registry record
    NCT05950139 · updated
  10. Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    BioNTech SE
    Study site
    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
    Registry record
    NCT05142189 · updated
  11. A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Seagen, a wholly owned subsidiary of Pfizer
    Study site
    Sidney Kimmel Comprehensive Cancer at Johns Hopkins
    Registry record
    NCT06131840 · updated
  12. A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Incyte Corporation
    Study site
    Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins
    Registry record
    NCT06179160 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Baltimore, MD on ClinicalTrials.gov.

Prostate cancer studies recruiting in Baltimore

  1. Robot-Assisted Prostate Biopsy With a Novel Ultrasound Probe

    • Phase 1
    • Ages 40 to 75
    • Male participants
    Sponsor
    Johns Hopkins University
    Study site
    Johns Hopkins Hospital
    Registry record
    NCT07271017 · updated
  2. Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

    • Phase 1
    • Ages 18 to 100
    • Male participants
    Sponsor
    Janux Therapeutics
    Study site
    University of Maryland Greenebaum Comprehensive Cancer Center
    Registry record
    NCT05519449 · updated
  3. FOG-001 in Locally Advanced or Metastatic Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Parabilis Medicines, Inc.
    Study site
    Johns Hopkins University, The Sidney Kimmel Comprehensive Cancer Center
    Registry record
    NCT05919264 · updated
  4. Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer

    • Phase 1
    • Ages 18 and older
    • Male participants
    Sponsor
    Acerand Therapeutics (Hong Kong) Limited
    Study site
    University of Maryland, Greenebaum Comprehensive Cancer Center
    Registry record
    NCT06801236 · updated
  5. A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC

    • Phase 1/2
    • Ages 18 and older
    • Male participants
    Sponsor
    Pathos AI, Inc.
    Study site
    Johns Hopkins Hospital
    Registry record
    NCT06785636 · updated
  6. Enzalutamide Implants (Enolen) in Patients With Prostate Cancer

    • Phase 1
    • Ages 21 and older
    • Male participants
    Sponsor
    Alessa Therapeutics Inc.
    Study site
    Johns Hopkins University School of Medicine
    Registry record
    NCT06257693 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Baltimore, MD on ClinicalTrials.gov.

Melanoma studies recruiting in Baltimore

  1. Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Johns Hopkins University/Sidney Kimmel Cancer Center
    Registry record
    NCT05896839 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Baltimore, MD on ClinicalTrials.gov.

Lymphoma studies recruiting in Baltimore

  1. The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

    • Phase 1/2
    • Up to age 22
    • All sexes
    Sponsor
    PedAL BCU, LLC
    Study sites
    Johns Hopkins University/Sidney Kimmel Cancer Center · Sinai Hospital of Baltimore
    Registry record
    NCT04726241 · updated
  2. A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

    • Phase 1/2
    • Ages 12 and older
    • All sexes
    Sponsor
    Nuvalent Inc.
    Study site
    John Hopkins University
    Registry record
    NCT05384626 · updated
  3. A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma

    • Phase 1/2
    • From 6 months, up to 30 years
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    Johns Hopkins University
    Registry record
    NCT05533775 · updated
  4. A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

    • Early Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    AIDS Malignancy Consortium
    Study site
    Johns Hopkins University/Sidney Kimmel Cancer Center
    Registry record
    NCT04139304 · updated
  5. Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

    • Early Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Study site
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Registry record
    NCT06398457 · updated
  6. CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

    • Phase 1/2
    • From 12 months, up to 21 years
    • All sexes
    Sponsor
    Children's Oncology Group
    Study site
    Johns Hopkins University/Sidney Kimmel Cancer Center
    Registry record
    NCT04870944 · updated
  7. Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Imugene Limited
    Study site
    University of Maryland
    Registry record
    NCT03666000 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Baltimore, MD on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in Baltimore

  1. Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Revolution Medicines, Inc.
    Study site
    The Sidney Kimmel Comprehensive Cancer Center at John Hopkins
    Registry record
    NCT06445062 · updated
  2. KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Study site
    Sidney Kimmel Comprehensive Cancer Center
    Registry record
    NCT06411691 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Baltimore, MD on ClinicalTrials.gov.

Ask about studies near Baltimore

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 1, including early Phase 1 and combined Phase 1/2, as each study is coded in the registry.

Phase 1 Cancer Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 927-9038

or send a short form

How should we reach you?

Call